利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

9 条记录 (耗时 0.029 秒)

    METHOD OF IMPROVING CHARACTERISTICS OF PROTEINS
    1.
    发明申请
    METHOD OF IMPROVING CHARACTERISTICS OF PROTEINS 审中-公开

    公开(公告)号：US20190078081A1

    公开(公告)日：2019-03-14

    申请号：US15555276

    申请日：2016-05-16

    申请人： FULL SPECTRUM GENETICS, INC

    发明人： Robert DuBridge

    IPC分类号： C12N15/10 ,  C07K1/04 ,  C07K16/00

    摘要： The invention provides efficient methods for combining single-substitution libraries of nucleic acids that span and encode proteins of interest and for selecting resultant mutant proteins after expression which have improved properties or characteristics. Specifically, the methods comprising synthesizing a single substitution library for each of a plurality of domains of a protein; expressing separately each member of each single substitution library as a pre-candidate protein; selecting members of each single substitution library which encode pre-candidate proteins which exhibit an improvement in the one or more predetermined characteristics to form a selected library; shuffling members or the selected libraries in a PCR to produce a combinatorial shuffled library; expressing members of the shuffled library as candidate proteins; and selecting mutant proteins which have improved properties or characteristics.

    Method of improving characteristics of proteins
    2.
    发明授权
    Method of improving characteristics of proteins 有权

    公开(公告)号：US10526597B2

    公开(公告)日：2020-01-07

    申请号：US15555276

    申请日：2016-05-16

    申请人： Full Spectrum Genetics, Inc.

    发明人： Robert DuBridge

    IPC分类号： C40B30/04 ,  C12N15/10 ,  C07K1/04 ,  C07K16/00 ,  C40B10/00 ,  C40B40/02 ,  C40B40/10

    摘要： The invention provides efficient methods for combining single-substitution libraries of nucleic acids that span and encode proteins of interest and for selecting resultant mutant proteins after expression which have improved properties or characteristics. Specifically, the methods comprising synthesizing a single substitution library for each of a plurality of domains of a protein; expressing separately each member of each single substitution library as a pre-candidate protein; selecting members of each single substitution library which encode pre-candidate proteins which exhibit an improvement in the one or more predetermined characteristics to form a selected library; shuffling members or the selected libraries in a PCR to produce a combinatorial shuffled library; expressing members of the shuffled library as candidate proteins; and selecting mutant proteins which have improved properties or characteristics.

    PARALLEL DETERMINATION OF COMPETITIVE BINDING AND TARGET SPECIFICITY OF A BINDING COMPOUND LIBRARY BY HIGH-THROUGHPUT DNA SEQUENCING
    5.
    发明申请
    PARALLEL DETERMINATION OF COMPETITIVE BINDING AND TARGET SPECIFICITY OF A BINDING COMPOUND LIBRARY BY HIGH-THROUGHPUT DNA SEQUENCING 审中-公开
    竞争性结合的并行确定和通过高通量DNA序列的结合化合物图谱的目标特异性

    公开(公告)号：US20140235483A1

    公开(公告)日：2014-08-21

    申请号：US14181695

    申请日：2014-02-16

    申请人： Full Spectrum Genetics, Inc.

    发明人： Robert DuBridge

    IPC分类号： G01N33/53

    CPC分类号： G01N33/5308 ,  G01N33/6845

    摘要： The invention is directed to a method for analyzing the competitive binding and target (or ligand) specificity of large numbers of candidate binding compounds with respect to a predetermined reference compound. That is, the invention provides a method for essentially conducting a massively parallel ELISA on each member of an entire library of candidate binding compounds at the same time. Instead of determining binding characteristics from a series of colorimetric or fluorometric readouts, such characteristics are determined from a series of frequencies of bound and unbound library members which, in turn, are determined by high-throughput sequencing of their encoding nucleic acids. In one aspect, predetermined reference compounds are proteins and candidate binding compounds are members of a mutant library based on or related to, the predetermined reference compound.

    摘要翻译： 本发明涉及一种用于分析大量候选结合化合物相对于预定参考化合物的竞争性结合和靶（或配体）特异性的方法。 也就是说，本发明提供了一种基本上同时对候选结合化合物的整个文库的每个成员进行大规模平行ELISA的方法。 不是从一系列比色或荧光读出中确定结合特征，而是从结合和未结合的文库成员的一系列频率确定这些特征，这些频率又由其编码核酸的高通量测序确定。 在一个方面，预定的参考化合物是蛋白质，候选结合化合物是基于或与预定参考化合物相关的突变文库的成员。

    Anti-TNFα binding compounds and uses thereof
    7.
    发明授权
    Anti-TNFα binding compounds and uses thereof 有权

    公开(公告)号：US10947305B2

    公开(公告)日：2021-03-16

    申请号：US15555234

    申请日：2016-03-14

    申请人： Full Spectrum Genetics, Inc.

    发明人： Robert DuBridge ,  Veronica Juan

    IPC分类号： C07K16/00 ,  C07K16/24

    摘要： The present invention is directed to novel Anti-TNFα antibody binding compounds and methods of using the same. Anti-TNFα antibody binding compounds of the invention comprise novel heavy chain immunoglobulin polypeptides of portions thereof. In some embodiments, the invention also includes pharmaceutical compositions comprising at least one Anti-TNFα antibody binding compound. The invention further provides the use of an Anti-TNFα antibody binding compound of the invention in the preparation of a medicament for the therapeutic and/or prophylactic treatment of a disorder.

    NOVEL ANTI-TNFalpha BINDING COMPOUNDS AND USES THEREOF
    8.
    发明申请
    NOVEL ANTI-TNFalpha BINDING COMPOUNDS AND USES THEREOF 审中-公开

    公开(公告)号：US20180051076A1

    公开(公告)日：2018-02-22

    申请号：US15555234

    申请日：2016-03-14

    申请人： Full Spectrum Genetics, Inc.

    发明人： Robert DuBridge ,  Veronica Juan

    IPC分类号： C07K16/24

    CPC分类号： C07K16/241 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/92

    摘要： The present invention is directed to novel Anti-TNFα antibody binding compounds and methods of using the same. Anti-TNFα antibody binding compounds of the invention comprise novel heavy chain immunoglobulin polypeptides of portions thereof. In some embodiments, the invention also includes pharmaceutical compositions comprising at least one Anti-TNFα antibody binding compound. The invention further provides the use of an Anti-TNFα antibody binding compound of the invention in the preparation of a medicament for the therapeutic and/or prophylactic treatment of a disorder.